Tecentriq SC (Atezolizumab)

atezolizumab 1.875 g/15 mL injection, 15 mL vial · INJECTION · PBS code 14267X

STREAMLINED

What it costs

AU$6747.37 PBS-determined price per 1 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2024-08-01.
• Repeats: 7.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen

Patient must be undergoing combination treatment with bevacizumab until disease progression, unless not tolerated; AND

Patient must have previously received PBS-subsidised treatment with this drug in this line of treatment; AND

Patient must have stable or responding disease.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.